1227737-73-6

Basic information

• Product Name: 2-(4-(4-(2,6-dimethoxy-4-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-3-yl)phenoxy)butoxy)-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one
• Synonyms: 2-(4-(4-(2,6-dimethoxy-4-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-3-yl)phenoxy)butoxy)-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one
• CAS NO: 1227737-73-6
• Molecular Weight: 713.785
• Mol File: 1227737-73-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(4-(4-(2,6-dimethoxy-4-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-3-yl)phenoxy)butoxy)-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(4-(2,6-dimethoxy-4-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-3-yl)phenoxy)butoxy)-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one(1227737-73-6)
• EPA Substance Registry System: 2-(4-(4-(2,6-dimethoxy-4-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-3-yl)phenoxy)butoxy)-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one(1227737-73-6)

Safety Data

• Hazardous Substances Data: 1227737-73-6(Hazardous Substances Data)

Upstream product

• 106852-80-6 4-(t-butyldimethylsilyloxy)-3,5-dimethoxybenzaldehyde 
• 121-33-5 vanillin 
• 86-81-7 3,4,5-trimethoxy-benzaldehyde 
• 55-21-0 benzamide 
• 108012-55-1 2-(4-hydroxy-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one 
• 13400-02-7 3,4,5-trimethoxy styrene 
• 1272644-64-0 3-(4-(tert-butyldimethylsilyloxy)-3,5-dimethoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazole 
• 1227741-03-8 2,6-dimethoxy-4-(5-(3,4,5-trimethoxyphenyl)-4,5-dihydroisoxazol-3-yl)phenol 
• 1272644-78-6 2-(4-(4-bromobutoxy)-3-methoxyphenyl)-2,3-dihydroquinazolin-4(1H)-one 
• 1246651-17-1 4-(tert-butyl-dimethyl-silyloxy)-3,5-dimethoxybenzaldehyde oxime 

Relevant articles and documents

Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as anticancer agents

A series of new 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydro quinazolinone hybrids with different linker architectures have been designed and synthesized. These compounds have been evaluated for their anticancer activity. One of the compounds 4c amongst this series has shown promising anticancer activity. Further some detailed biological assays relating to the cell cycle aspects and tubulin depolymerization activity have been examined with a view to understand the mechanism of action of this conjugate.